Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2005

View Archived Issues

Medivir reflects on Q3 developments

Targeting mGluR1 for epilepsy

USP7: new target for cancer with inhibitors identified at Hybrigenics

Bioreductive prodrugs facilitate selective targeting of hypoxic tumor regions

Novel tumor-localizing agents described

R-112 disappoints in phase II comparative study in allergic rhinitis

Bausch & Lomb and PTC Therapeutics collaborate in ophthalmology

ArQule seeks to begin phase I studies with ARQ-197

Wyeth awarded new contract for development of therapeutic HIV vaccines

Alza modifies U.S. clinical development program for OROS Hydromorphone

Second approvable letter for diquafosol tetrasodium ophthalmic solution

New phase I study investigates INNO-105 in advanced solid malignancies

Private equity financing to support NeurogesX' development of Transacin

Bausch & Lomb licenses compounds from Cephalon for ophthalmic use

Provectus studies PV-10 for breast cancer in phase I trial

ACP-103 reduces haloperidol-induced akathisia in patients with schizophrenia

Phase I data on chemotherapeutic RH1 presented

S-18407, a novel alpha4beta1 integrin inhibitor, effective in murine Lyme arthritis

Opticin found to induce antiangiogenic effects in vitro and in vivo

New cancer vaccine activates host immune response

New agents described for treating cardiovascular disorders

Novel compounds with potential for inflammatory disorders imparted in patents

Recent patents report new treatments for thrombotic disorders

Preclinical studies reveal activity of BMS-354825 in various cancer types

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...